{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:00:56Z","timestamp":1768989656206,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejpb.2023.12.004","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T13:30:28Z","timestamp":1702387828000},"page":"148-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Aggregation of human plasma and of human blood induced in vitro by filgrastim originator product; effect of PEGylation"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8483-4130","authenticated-orcid":false,"given":"Tudor","family":"Arvinte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-5205","authenticated-orcid":false,"given":"Amelia","family":"Cudd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuri","family":"Ersayin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Darpin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Dowd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Brokx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.12.004_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2023.10.019","article-title":"Aggregation of human plasma and of human blood induced in vitro by pegfilgrastim originator formulation buffer and pegfilgrastim products","author":"Arvinte","year":"2023","journal-title":"Eur. J. Pharmaceut. Biopharmaceut."},{"key":"10.1016\/j.ejpb.2023.12.004_b0010","unstructured":"NEUPOGEN\u00ae (filgrastim) injection, for subcutaneous or intravenous use. Full Prescribing Information. Amgen Inc. Thousand Oaks, CA. 03\/2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/103353s5183lbl.pdf."},{"key":"10.1016\/j.ejpb.2023.12.004_b0015","series-title":"Characterization, Formulation, and Stability of Neupogen\u00ae (filgrastim), a Recombinant Human Granulocyte- Colony Stimulating FactorFormulation, Characterization, and Stability of Protein Drugs","first-page":"303","author":"Herman","year":"1996"},{"key":"10.1016\/j.ejpb.2023.12.004_b0020","unstructured":"Biosimilar Product Information. US Food and Drug Administration: https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information."},{"key":"10.1016\/j.ejpb.2023.12.004_b0025","unstructured":"NEULASTA\u00ae (pegfilgrastim) injection for subcutaneous use. Full Prescribing Information. Amgen Inc. Thousand Oaks, CA. 06\/2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125031s203lbl.pdf."},{"issue":"3","key":"10.1016\/j.ejpb.2023.12.004_b0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40259-015-0127-4","article-title":"Design rationale and development approach for Pegfilgrastim as a long-acting granulocyte colony-stimulating factor","volume":"29","author":"Arvedson","year":"2015","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.ejpb.2023.12.004_b0035","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2007.04.017","article-title":"Formulation of Neulasta (pegfilgrastim)","volume":"60","author":"Piedmonte","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.12.004_b0040","unstructured":"K.R. Feingold, 2021, Introduction to Lipids and Lipoproteins\u201d in: K.R. Feingold, B. Anawalt, M.R. Blackman, A. Boyce, G. Chrousos, E. Corpas, et al. (eds.), NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health; Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available at. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK305896\/?report=printable."},{"issue":"3","key":"10.1016\/j.ejpb.2023.12.004_b0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11743-001-0184-2","article-title":"Determination of Critical Micelle Concentration (CMC) of Nonionic Surfactants by Donor-Acceptor Interaction with Iodine and Correlation of CMC with Hydrophile-Lipophile Balance and Other Parameters of the Surfactants","volume":"4","author":"Hait","year":"2001","journal-title":"J. Surfact. Detergents."},{"issue":"1","key":"10.1016\/j.ejpb.2023.12.004_b0050","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/s41598-020-59346-z","article-title":"The ELISA detectability and potency of Pegfilgrastim decrease in physiological conditions: Key roles for aggregation and individual variability","volume":"10","author":"Xie","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2023.12.004_b0055","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1200\/JCO.2006.06.1663","article-title":"Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation","volume":"24","author":"Dekker","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejpb.2023.12.004_b0060","doi-asserted-by":"crossref","first-page":"2172292","DOI":"10.1080\/16078454.2023.2172292","article-title":"Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis","volume":"28","author":"Zhu","year":"2023","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.ejpb.2023.12.004_b0065","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4161\/mabs.24245","article-title":"Aggregation of biopharmaceuticals in human plasma and human serum. Implications for drug research and development","volume":"5","author":"Arvinte","year":"2013","journal-title":"mAbs"},{"key":"10.1016\/j.ejpb.2023.12.004_b0070","doi-asserted-by":"crossref","unstructured":"T. Arvinte, E. Poirier, C. Palais, Formation of aggregates after mixing therapeutic antibodies with human plasma depends on antibody formulation, in: A. Rosenberg, B. Demeule, (eds.), Biobetters. Protein Engineering to Approach the Curative, part of AAPS series entitled \u201cAdvances in Pharmaceutical Sciences\u201d, Springer, New York, 2015, pp. 91\u2013104. doi: 10.1007\/978-1-4939-2543-8.","DOI":"10.1007\/978-1-4939-2543-8_7"},{"key":"10.1016\/j.ejpb.2023.12.004_b0075","series-title":"Pharmaceutical Formulation: the Science and Technology of Dosage Forms","first-page":"288","author":"Arvinte","year":"2018"},{"key":"10.1016\/j.ejpb.2023.12.004_b0080","unstructured":"EMA: Annex I: Filgrastim HEXAL Summary of Product Characteristics. EMA https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/filgrastim-hexal-epar-product-information_en.pdf."},{"issue":"Supplement 1","key":"10.1016\/j.ejpb.2023.12.004_b0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-139086","article-title":"Real world risk of splenic rupture with G-CSF\/GM- CSF therapy: A pharmacovigilance assessment using FDA adverse event reporting system (FAERS) database","volume":"136","author":"Kaur","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejpb.2023.12.004_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222561","article-title":"Case report Spontaneous splenic rupture as a rare complication of G-CSF injection","author":"Benguerfi","year":"2018","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.ejpb.2023.12.004_b0095","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","article-title":"The spleen in local and systemic regulation of immunity","volume":"39","author":"Bronte","year":"2013","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.ejpb.2023.12.004_b0100","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/19420862.2015.1087636","article-title":"Dextrose-mediated aggregation of therapeutic monoclonal antibodies in human plasma: Implication of isoelectric precipitation of complement proteins","volume":"7","author":"Luo","year":"2015","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.ejpb.2023.12.004_b0105","doi-asserted-by":"crossref","first-page":"e1685814-1","DOI":"10.1080\/19420862.2019.1685814","article-title":"Defining the right diluent for intravenous infusion of therapeutic antibodies","volume":"12","author":"Luo","year":"2020","journal-title":"mAbs"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123003284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123003284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:54:46Z","timestamp":1760547286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123003284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":21,"alternative-id":["S0939641123003284"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.12.004","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aggregation of human plasma and of human blood induced in vitro by filgrastim originator product; effect of PEGylation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}